Exchange Capital Management Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Exchange Capital Management reduced its stake in Johnson & Johnson by 0.25% during the most recent quarter end. The investment management company now holds a total of 73,966 shares of Johnson & Johnson which is valued at $8,149,574 after selling 187 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Apr 12, 2016.Johnson & Johnson makes up approximately 3.47% of Exchange Capital Management’s portfolio.

Johnson & Johnson opened for trading at $110.07 and hit $110.4 on the upside on Friday, eventually ending the session at $110.18, with a gain of 0.31% or 0.34 points. The heightened volatility saw the trading volume jump to 1,00,57,921 shares. Company has a market cap of $304,026 M.

Other Hedge Funds, Including , Banced Corp reduced its stake in JNJ by selling 226 shares or 3.18% in the most recent quarter. The Hedge Fund company now holds 6,890 shares of JNJ which is valued at $759,140. Johnson & Johnson makes up approx 1.32% of Banced Corp’s portfolio.Kistler-tiffany Companies boosted its stake in JNJ in the latest quarter, The investment management firm added 1,932 additional shares and now holds a total of 42,013 shares of Johnson & Johnson which is valued at $4,578,157. Johnson & Johnson makes up approx 2.57% of Kistler-tiffany Companies’s portfolio.Baystate Wealth Management reduced its stake in JNJ by selling 218 shares or 0.89% in the most recent quarter. The Hedge Fund company now holds 24,330 shares of JNJ which is valued at $2,651,240. Johnson & Johnson makes up approx 0.58% of Baystate Wealth Management’s portfolio.New England Research Management boosted its stake in JNJ in the latest quarter, The investment management firm added 900 additional shares and now holds a total of 26,130 shares of Johnson & Johnson which is valued at $2,847,386. Johnson & Johnson makes up approx 2.45% of New England Research Management’s portfolio.Academy Capital Management Inctx reduced its stake in JNJ by selling 3,191 shares or 2.76% in the most recent quarter. The Hedge Fund company now holds 112,450 shares of JNJ which is valued at $12,253,677. Johnson & Johnson makes up approx 3.00% of Academy Capital Management Inctx’s portfolio.

On the company’s financial health, Johnson & Johnson reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jan 26, 2016. Analyst had a consensus of $1.42. The company had revenue of $17811.00 million for the quarter, compared to analysts expectations of $17856.07 million. The company’s revenue was down -2.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.27 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.